Cyclopharm Expands Technegas Footprint in U.S. Market

Cyclopharm Limited (AU:CYC) has released an update.

Cyclopharm Limited is expanding its presence in the U.S. healthcare market with its Technegas technology now installed in 17 prestigious medical institutions, including Massachusetts General Hospital and Stanford University Hospital. This growth follows U.S. FDA approval and Medicare reimbursement, driving revenue and highlighting Technegas’ role in advanced lung diagnostics. Cyclopharm’s strategy aims for sustainable growth and increased shareholder value through broader adoption of Technegas for various respiratory conditions.

For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.